Virax Biolabs Group Ltd - Class A VRAX

NAS: VRAX | ISIN: KYG9495L1251   30/05/2025
0,963 USD (+0,47%)
(+0,47%)   30/05/2025

18 maart 2025 · Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes · Persbericht

13 maart 2025 · Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting · Persbericht

5 maart 2025 · Virax Biolabs to Present at 19th World Immune Regulation Meeting · Persbericht

9 september 2024 · Virax Biolabs Presents at H.C. Wainwright's 26th Annual Global Investment Conference · Persbericht

29 augustus 2024 · Virax Biolabs to Participate at 7th European Congress of Immunology · Persbericht

28 augustus 2024 · Virax Biolabs Announces Distribution Agreement to Commercialize Mpox (formerly Monkeypox) Virus RT-PCR Detection Kits in Europe and the Middle East · Persbericht

23 augustus 2024 · Virax Biolabs Group Limited Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares · Persbericht

22 augustus 2024 · Virax Biolabs Group Limited Announces $5 Million Registered Direct Offering of Ordinary Shares · Persbericht

25 april 2024 · Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024 · Persbericht

16 april 2024 · Virax Biolabs to Participate at ESCMID Global 2024 · Persbericht

15 maart 2024 · Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency · Persbericht

7 februari 2023 · Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM) · Persbericht

22 september 2022 · Virax Biolabs Group Limited Announces Distribution Agreement to Market Monkeypox Virus Real-Time PCR Detection Kit with Cosmos Holdings Inc. · Persbericht

Mijn selecties